[8] Novo Nordisk announced late at the 2025 European Association for the Study of Diabetes (EASD) annual meeting that in the REDEFINE 1 study, [9] cagrilintide provided clinically significant weight loss, with a mean reduction in body weight of 11.8% compared to 2.3% with placebo after 68 weeks, considering adherence of all participants to treatment
Bibliography Neuro20 PRO System Overview
It's important to note that Semaglutide should always be used under the guidance of a healthcare professional, who will monitor its effectiveness, potential side effects, and ensure its appropriate use in achieving weight loss goals
The next frontier in metabolic health: Cagrilintide-Semaglutide and the evolving landscape of therapies
In some cases, it may cause side effects such as gastrointestinal problems, numbness, or a fast heart rate
Also, discuss the benefits, risks, and expected outcomes of the procedure, and follow any pre- and post-treatment care instructions provided